Early research (Phase 1)Looking for participantsNCT03829540What this trial is testingCD4CAR for CD4+ Leukemia and LymphomaWho this might be right forT-cell LymphomaT-cell Leukemia Huda Salman 20
Testing effectiveness (Phase 2)UnknownNCT04553393What this trial is testingDecitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor BurdenWho this might be right forRefractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden Chinese PLA General Hospital 80
Very early researchUnknownNCT04966143What this trial is testingClinical Study of LY011 in the Treatment of Advanced Pancreatic CancerWho this might be right forPancreatic Cancer Shanghai Longyao Biotechnology Inc., Ltd. 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03919240What this trial is testingCAR-T Cell Therapy Targeting to CD19 for R/R ALLWho this might be right forAcute Lymphoblastic Leukemia With Failed Remission The First Affiliated Hospital of Soochow University 196
Not applicableStudy completedNCT02813252What this trial is testingLong-Term Follow-up Study for Patients Previously Treated With JCAR015Who this might be right forAcute Lymphoblastic Leukemia Juno Therapeutics, a Subsidiary of Celgene 15
Early research (Phase 1)Study completedNCT02746952What this trial is testingDose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic LeukaemiaWho this might be right forB-cell Acute Lymphoblastic Leukemia Institut de Recherches Internationales Servier 25
Early research (Phase 1)Looking for participantsNCT07647744What this trial is testingTo Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal CancerWho this might be right forRenal Cell Carcinoma (RCC) Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)WithdrawnNCT07071909What this trial is testingImmune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T CellsWho this might be right forMalignancyCancerHematological Malignancies+4 more UNC Lineberger Comprehensive Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT05554939What this trial is testingAllogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHLWho this might be right forNon Hodgkin's Lymphoma Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05336383What this trial is testingPhase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaWho this might be right forMultiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT06090864What this trial is testingATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 CellsWho this might be right forHodgkin LymphomaRelapseRefractory UNC Lineberger Comprehensive Cancer Center 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT06581198What this trial is testingRapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Who this might be right forLupus Erythematosus, SystemicLupus Nephritis Novartis Pharmaceuticals 179
Early research (Phase 1)Looking for participantsNCT06191887What this trial is testingB-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesWho this might be right forB-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more Mayo Clinic 27
Early research (Phase 1)Study completedNCT04134117What this trial is testingTisagenlecleucel In Primary CNS LymphomaWho this might be right forPrimary CNS LymphomaRefractory Primary CNS LymphomaRelapsed Primary CNS Lymphoma Matthew J. Frigault, M.D. 13
Not applicableUnknownNCT05414162What this trial is testingMultiparametric Cardiac MRI in Patients Under CAR T-cell TherapyWho this might be right forDLBCLMultiple MyelomaCytokine Release Syndrome+6 more University Hospital, Bonn 60
Testing effectiveness (Phase 2)Study completedNCT05032820What this trial is testingUpfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaWho this might be right forMultiple Myeloma Medical College of Wisconsin 40
Early research (Phase 1)UnknownNCT04981691What this trial is testingAnti-mesothelin CAR-T Cells With Advanced Refractory Solid TumorsWho this might be right forRefractory Malignant Solid Neoplasm Ruijin Hospital 12
Early research (Phase 1)Looking for participantsNCT05773040What this trial is testingJV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasWho this might be right forLymphomasB-cell Lymphomas M.D. Anderson Cancer Center 33
Early research (Phase 1)Looking for participantsNCT06461624What this trial is testingClinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaWho this might be right forAdvanced Hepatocellular Carcinoma Zhejiang University 15
Early research (Phase 1)WithdrawnNCT07297160What this trial is testingCD70.CAR for CD70+ Lymphoma, Myeloma and Solid TumorsWho this might be right forLymphomaMyelomaSolid Tumors+2 more Baylor College of Medicine